The public health legacy of slavery
Slavery ended decades ago, but its impact is still felt today, including in the health disparities faced by African Americans.
Related Articles
Here are the dozens of weight loss drugs in development to catch a booming market
Want to know which drugs could soon compete with Wegovy or Mounjaro? The STAT Obesity Drug Tracker is following dozens of candidates.
Invisible in the data: Broad ‘Asian American’ category obscures health disparities
Blending together the highly diverse pool of Asian Americans in widely used metrics obscures vast differences in their health.
Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
A STAT investigation found artificial intelligence is driving Medicare Advantage denials to new heights, cutting off care for seniors.
The Equity in Heart Transplant Project
Our mission is to empower patients with heart failure by eliminating financial barriers and making life-saving heart transplants accessible.
Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
A STAT investigation found artificial intelligence is driving Medicare Advantage denials to new heights, cutting off care for seniors.
Here are the dozens of weight loss drugs in development to catch a booming market
Want to know which drugs could soon compete with Wegovy or Mounjaro? The STAT Obesity Drug Tracker is following dozens of candidates.
stats
The National Institute for Occupational Safety and Health’s (NIOSH) Impact Wellbeing ™ campaign gives hospital leaders evidence-informed solutions to reduce healthcare worker burnout, sustain wellbeing,…
A nonprofit group is pushing to get estrogen FDA approved for gender-affirming care
The FDA gave feedback on a nonprofit group’s proposal for a phase III clinical trial focused on estradiol as a gender-affirming treatment for trans and…
A New Match for Menopausal Weight Gain: Ozempic
Weight gain is one of the most common concerns among women going through menopause. New drugs could change that.
White House official dings Bristol-Myers Squibb for fighting off generic competition
A White House Domestic Policy Council deputy criticized Bristol-Myers Squibb’s efforts to fight off generic competition for a popular blood thinner.